Trends in the incidence of diabetes mellitus: results from the Global Burden of Disease Study 2017 and implications for diabetes mellitus prevention

Liu, Jinli; Ren, Zhen; Qiang, Hui; Wu, Jine; Shen, Mingwang; Zhang, Lei; Lyu, Jun

doi:10.1186/s12889-020-09502-x

Cited by 196 publications

(123 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Type 2 diabetes (T2D) is a chronic metabolic condition associated with hyperglycemia and insulin resistance, whose incidence is continuously increasing worldwide [ 1 ]. Hyperglycemia is deemed the principal pathogenic factor in T2D since high blood glucose levels are implicated in major health complications including cardiovascular diseases, neuropathy, nephropathy, and retinopathy [ 2 , 3 ].…”

Section: Introductionmentioning

confidence: 99%

An Integrated Peptidomics and In Silico Approach to Identify Novel Anti-Diabetic Peptides in Parmigiano-Reggiano Cheese

Martini

Solieri

Cattivelli

et al. 2021

Biology

View full text Add to dashboard Cite

Inhibition of key metabolic enzymes linked to type-2-diabetes (T2D) by food-derived compounds is a preventive emerging strategy in the management of T2D. Here, the impact of Parmigiano-Reggiano (PR) cheese peptide fractions, at four different ripening times (12, 18, 24, and 30 months), on the enzymatic activity of α-glucosidase, α-amylase, and dipeptidyl peptidase-IV (DPP-IV) as well as on the formation of fluorescent advanced glycation end-products (fAGEs) was assessed. The PR peptide fractions were able to inhibit the selected enzymes and fAGEs formation. The 12-month-ripening PR sample was the most active against the three enzymes and fAGEs. Mass spectrometry analysis enabled the identification of 415 unique peptides, 54.9% of them common to the four PR samples. Forty-nine previously identified bioactive peptides were found, mostly characterized as angiotensin-converting enzyme-inhibitors. The application of an integrated approach that combined peptidomics, in silico analysis, and a structure–activity relationship led to an efficient selection of 6 peptides with potential DPP-IV and α-glucosidase inhibitory activities. Peptide APFPE was identified as a potent novel DPP-IV inhibitor (IC50 = 49.5 ± 0.5 μmol/L). In addition, the well-known anti-hypertensive tripeptide, IPP, was the only one able to inhibit the three digestive enzymes, highlighting its possible new and pivotal role in diabetes management.

show abstract

Section: Introductionmentioning

confidence: 99%

An Integrated Peptidomics and In Silico Approach to Identify Novel Anti-Diabetic Peptides in Parmigiano-Reggiano Cheese

Martini

Solieri

Cattivelli

et al. 2021

Biology

View full text Add to dashboard Cite

show abstract

“…Although the development of this pathology shows high hereditability, T2DM seems to be caused by a combination of lifestyle and genetic factors [ 25 ]. In this sense, T2DM prevalence is increasing in children and younger adults, due to rising levels of obesity, sedentary lifestyle and inappropriate diet [ 26 , 27 ].…”

Section: Prediabetes and Type 2 Diabetes Mellitusmentioning

confidence: 99%

“…On the other hand, db/db mice on IF show a reduction of NFκB activation and decreased LPS levels, associated with a significant improvement of cognitive function, limited neuroinflammatory response, restructured gut microbiota and metabolites [ 27 , 220 ] and reduced insulin resistance [ 207 ]. Other studies in db/db mice on IF regimen for 28 days have reported a reduction of Enterococcus , Streptococcus , Enterococcaceae , Arthromitus , Rummeliibacillus that cause inflammation, while increasing Lactobacillus , accompanied by the attenuation of behavioral alterations [ 207 ].…”

Section: Diet Inflammation and Gut Microbiota In T2dm Modelsmentioning

confidence: 99%

“…It has also been shown that family Helicobacteraceae is increased in 3–8 month-old APP/PS1 mice, 6 month-old 5xFAD mice and after HFD administration [ 132 , 134 , 206 ], supporting similar changes in AD and metabolic disease models. Interestingly, previous studies suggest that AD and T2DM pathologies can improve through the treatment of pre-and probiotics [ 87 , 151 , 152 , 153 , 248 , 258 ], caloric restriction diets [ 27 , 157 , 207 , 220 ] or antioxidants [ 154 ], helping to regulate intestinal dysbiosis and reduce the inflammation.…”

Section: Common Microbiota Alterations In Ad T2dm and Mixed Preclmentioning

confidence: 99%

See 1 more Smart Citation

Alzheimer’s Disease and Diabetes: Role of Diet, Microbiota and Inflammation in Preclinical Models

et al. 2021

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is the most common cause of dementia. Epidemiological studies show the association between AD and type 2 diabetes (T2DM), although the mechanisms are not fully understood. Dietary habits and lifestyle, that are risk factors in both diseases, strongly modulate gut microbiota composition. Also, the brain-gut axis plays a relevant role in AD, diabetes and inflammation, through products of bacterial metabolism, like short-chain fatty acids. We provide a comprehensive review of current literature on the relation between dysbiosis, altered inflammatory cytokines profile and microglia in preclinical models of AD, T2DM and models that reproduce both diseases as commonly observed in the clinic. Increased proinflammatory cytokines, such as IL-1β and TNF-α, are widely detected. Microbiome analysis shows alterations in Actinobacteria, Bacteroidetes or Firmicutes phyla, among others. Altered α- and β-diversity is observed in mice depending on genotype, gender and age; therefore, alterations in bacteria taxa highly depend on the models and approaches. We also review the use of pre- and probiotic supplements, that by favoring a healthy microbiome ameliorate AD and T2DM pathologies. Whereas extensive studies have been carried out, further research would be necessary to fully understand the relation between diet, microbiome and inflammation in AD and T2DM.

show abstract

“…Prevalence rates for diabetes mellitus continue to rise across countries and continents ( 1 – 7 ). This has been exacerbated by over 100% increases in incident cases of diabetes mellitus from 1990, rising to 22.936 million in 2017 ( 8 ), which has resulted in an estimated 463 million people worldwide with diabetes mellitus in 2019 ( 8 , 9 ). These prevalence rates are expected to grow unless addressed.…”

Section: Introductionmentioning

confidence: 99%

The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future

Godman

Haque

Leong

et al. 2021

Front. Public Health

View full text Add to dashboard Cite

Background: Diabetes mellitus rates continue to rise, which coupled with increasing costs of associated complications has appreciably increased global expenditure in recent years. The risk of complications are enhanced by poor glycaemic control including hypoglycaemia. Long-acting insulin analogues were developed to reduce hypoglycaemia and improve adherence. Their considerably higher costs though have impacted their funding and use. Biosimilars can help reduce medicine costs. However, their introduction has been affected by a number of factors. These include the originator company dropping its price as well as promoting patented higher strength 300 IU/ml insulin glargine. There can also be concerns with different devices between the manufacturers.Objective: To assess current utilisation rates for insulins, especially long-acting insulin analogues, and the rationale for patterns seen, across multiple countries to inform strategies to enhance future utilisation of long-acting insulin analogue biosimilars to benefit all key stakeholders.Our approach: Multiple approaches including assessing the utilisation, expenditure and prices of insulins, including biosimilar insulin glargine, across multiple continents and countries.Results: There was considerable variation in the use of long-acting insulin analogues as a percentage of all insulins prescribed and dispensed across countries and continents. This ranged from limited use of long-acting insulin analogues among African countries compared to routine funding and use across Europe in view of their perceived benefits. Increasing use was also seen among Asian countries including Bangladesh and India for similar reasons. However, concerns with costs and value limited their use across Africa, Brazil and Pakistan. There was though limited use of biosimilar insulin glargine 100 IU/ml compared with other recent biosimilars especially among European countries and Korea. This was principally driven by small price differences in reality between the originator and biosimilars coupled with increasing use of the patented 300 IU/ml formulation. A number of activities were identified to enhance future biosimilar use. These included only reimbursing biosimilar long-acting insulin analogues, introducing prescribing targets and increasing competition among manufacturers including stimulating local production.Conclusions: There are concerns with the availability and use of insulin glargine biosimilars despite lower costs. This can be addressed by multiple activities.

show abstract

Trends in the incidence of diabetes mellitus: results from the Global Burden of Disease Study 2017 and implications for diabetes mellitus prevention

Cited by 196 publications

References 40 publications

An Integrated Peptidomics and In Silico Approach to Identify Novel Anti-Diabetic Peptides in Parmigiano-Reggiano Cheese

An Integrated Peptidomics and In Silico Approach to Identify Novel Anti-Diabetic Peptides in Parmigiano-Reggiano Cheese

Alzheimer’s Disease and Diabetes: Role of Diet, Microbiota and Inflammation in Preclinical Models

The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future

Contact Info

Product

Resources

About